|
Alan J. Lewis, Ph.D., joined Novocell in February 2006 as president, chief executive officer and director. Prior to Novocell, Dr. Lewis served as CEO and director of Signal Pharmaceuticals before its acquisition in 2000 by Celgene, a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for cancer and immunological diseases. He then served as president of the Signal Research Division at Celgene. Dr. Lewis previously held the position of vice president of research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy and bone metabolism diseases. Dr. Lewis currently serves as a director of BioMarin Pharmaceutical, Inc. and Cytochroma, Inc. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University. | 